Alzheimer Disease

Food insecurity was associated with an increased risk of dementia, poorer memory function, and faster memory decline in older adults.

The drug may be a risk factor for dementia-related illnesses.

In May 2023, the FDA approved brexpiprazole as the first and only drug to receive approval for treatment of agitation associated with Alzheimer Disease dementia.

Study also showed that 76% of individuals treated with lecanemab-irmb had no deterioration in the tau positron emission tomography (PET) subset.

A weekly dose of injectable lecanemab-irmb (Leqembi) could allow patients with Alzheimer disease to receive the drug at home instead of visiting an infusion center twice per month.

Approximately 96% physicians feel it is important to assess patients aged 60 years and older for cognitive impairment, but 48% of these patients have no had assessments from their physician.

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody that targets amyloid plaques, which are thought to play a role in the development and progression of Alzheimer disease.

Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.

Maintaining a purpose in life has the potential to reduce apathy related to dementia and cognitive decline.

In clinical trials, lecanemab showed a reduction of amyloid beta plaque in patients with Alzheimer disease.

Testosterone may protect the brain against dementia pathology, but the association has not been proven.

Infections were associated with a 1.49-fold increase in the rate of dementia in both the short- and long-term rates, however, the increases were greater in the short term.

Symptoms of dementia can be difficult to differentiate from typical age-related behavior changes and other common and potentially curable conditions.

One IVIG product showed overall improvement in neuroprotection, including alleviating cognitive decline and ameliorating AB deposition in Alzheimer disease.

Heart health may influence long-term brain health as early as middle age.

This social determinant of health could have the same level of negative impact on health as the experience of racism, poverty, or low education.

UB-311 has shown to be well-tolerated with a durable antibody response in a previous phase 1 trial, and new results from a phase 2a study support its continued development.

Through previous literature, investigators found that intervention with nutritional supplements may help to improve cognitive performance and reduce the severity of memory impairment in adults with Alzheimer disease.

Advancements in the development of amyloid-targeting monoclonal antibodies show promise for treating Alzheimer disease, but there have been concerns around cost, adverse reactions, and inequity of care for marginalized patients.

Pharmacists play a key role in the management of modern monoclonal antibody treatments for Alzheimer disease.

New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.

The research narrows the most at-risk populations and how to mitigate the impacts on adults with ADRD.

Participants were able to stop treatment after achieving amyloid plaque clearance and experience lasting results.

Tooth loss and gum disease may play a role in the health of the brain area that controls thinking and memory.

Lecanemab-irmb is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer disease.

To slow the production of MCI and dementia, utilizing more ways of establishing the diagnoses for women can prevent the progression.

Utilizing longitudinal assessments of language impairment and clinical progression could help identify challenges earlier.

Leqembi is an intravenous injection for the treatment of Alzheimer disease.

Brexpiprazole was associated with a statistically and clinically meaningful improvement in agitative behaviors caused by dementia compared to placebo.

Lack of awareness, or anosognosia, may be present up to 2 to 3 years before an Alzheimer dementia diagnosis is made.